Novo Nordisk AS Class B NONOF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
GLP-1 drugs could ease back and knee pain, but doctors say there are risks for older adults
-
Novo Nordisk Says FDA Review of Hemophilia Drug Is Hitting Delays
-
Eli Lilly Says Zepbound Delivers Greater Weight Loss Than Higher-Dose Version of Novo's Wegovy
-
Taking Ozempic and worried about vision loss? This test can help you understand your risk.
-
Novo Nordisk strikes second licensing deal since frosty capital-markets day
-
Novo Inks Weight-Loss Licensing Deal With Hengrui Pharma
-
After capital-markets day flop, Novo strikes licensing deal that sends a Swedish company's stock soaring
-
Novo Nordisk to Pay Up to $1.3 Billion for Nanexa's Drug Delivery Technology
Trading Information
- Previous Close Price
- $37.69
- Day Range
- $36.45–40.24
- 52-Week Range
- $34.00–62.75
- Bid/Ask
- $39.40 / $40.15
- Shares Outstanding
- 4.41B
- Market Cap
- $176.73B
- Volume/Avg
- 79,893 / 97,163
Key Statistics
- Price/Earnings (Normalized)
- 8.44
- Price/Sales
- 3.32
- Dividend Yield (Trailing)
- 4.78%
- Dividend Yield (Forward)
- 4.78%
- Dividend Payment Schedule
- Mar, Aug
- Total Yield
- 5.00%
Company Profile
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Value
- Total Number of Employees
- 68,794
- Website
- https://www.novonordisk.com
Competitors
Valuation
|
Metric
|
NONOF
|
SNY
|
AZN
|
|---|---|---|---|
Price/Earnings (Normalized) | 8.44 | 11.11 | 14.55 |
Price/Book Value | 5.41 | 1.29 | 4.86 |
Price/Sales | 3.32 | 1.66 | 4.06 |
Price/Cash Flow | 8.26 | 6.87 | 16.09 |
Price/Earnings
NONOF
SNY
AZN
Financial Strength
|
Metric
|
NONOF
|
SNY
|
AZN
|
|---|---|---|---|
Quick Ratio | 0.54 | 0.49 | 0.66 |
Current Ratio | 0.79 | 0.99 | 0.89 |
Interest Coverage | — | 8.05 | 7.99 |
Quick Ratio
NONOF
SNY
AZN
Profitability
|
Metric
|
NONOF
|
SNY
|
AZN
|
|---|---|---|---|
Return on Assets (Normalized) | — | 7.96% | 9.00% |
Return on Equity (Normalized) | — | 14.96% | 21.69% |
Return on Invested Capital (Normalized) | — | 11.28% | 14.36% |
Return on Assets
NONOF
SNY
AZN
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|gtlq$nn | LOCK|f^w | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|fB?t!n | LOCK|>Th | $612B | |||
| AbbVie Inc
ABBV
| LOCK|Zv!Q@<> | LOCK|@>f | $501B | |||
| Merck & Co Inc
MRK
| LOCK|!q%!S># | LOCK|Xl | $364B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|!^m>!!! | LOCK|%Sv | $356B | |||
| Novartis AG ADR
NVS
| LOCK|rZp#>jV | LOCK|?F | $280B | |||
| AstraZeneca PLC
AZN
| LOCK|<G?@$P< | LOCK|N? | $253B | |||
| Amgen Inc
AMGN
| LOCK|s@VpfR?Z | LOCK|!> | $230B | |||
| Gilead Sciences Inc
GILD
| LOCK|%wCb@M# | LOCK|qC% | $190B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|qq>??% | LOCK|kj | $169B |
United States